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 14 
ABSTRACT  15 
 Background – The National Health Service England, Commissioning for Quality and Innovation for 16 
antimicrobial resistance (CQUIN AMR) aims to reduce the total antibiotic consumption and the 17 
use of certain broad-spectrum antibiotics in secondary care. However, robust baseline antibiotic 18 
use data are lacking for hospitalised children. In this study, we aim to describe, compare and 19 
explain the prescription patterns of antibiotics within and between paediatric units in the UK and 20 
to provide a baseline for antibiotic prescribing for future improvement using CQUIN AMR 21 
guidance. 22 
 Method - We conducted a cross sectional study using a point prevalence survey (PPS) in 61 23 
paediatric units across the UK. The standardised study protocol from the Antimicrobial Resistance 24 
and Prescribing in European Children (ARPEC) project was used. All inpatients under 18 years of 25 
age present in the participating hospital the day of the study were included except neonates. 26 
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 Results – A total of 1247 (40.9%) of 3047 children hospitalised on the day of the PPS were on 1 
antibiotics. The proportion of children receiving antibiotics showed a wide variation between both 2 
district general and tertiary hospitals, with 36.4% (Confidence Interval 95% [CI95] 33.4-39.4) and 3 
43.0% (CI95, 40.9-45.1) of children prescribed antibiotics respectively. About a quarter of children 4 
on antibiotic therapy received either a medical or surgical prophylaxis with parenteral 5 
administration being the main prescribed route for antibiotics (>60% of the prescriptions for both 6 
type of hospitals). General paediatrics units were surprisingly high prescribers of critical broad-7 
spectrum antibiotics, i.e. carbapenems and piperacillin-tazobactam.  8 
 Conclusions - We provide a robust baseline for antibiotic prescribing in hospitalised children in 9 
relation to current national stewardship efforts in the UK. Repeated PPS with further linkage to 10 
resistance data need to be part of the antibiotic stewardship strategy to tackle the issue of 11 
suboptimal antibiotic use in hospitalised children.  12 
 13 
Article summary 14 
Strengths and limitations of this study 15 
 We used a simple, rigorous, validated and standardised point prevalence method to provide the 16 
baseline for antimicrobial prescribing in hospitalised children to assess current and future national 17 
strategies in the UK. .  18 
 Data were collected from a large sample of hospitalised children on antibiotics (n=1247) including 19 
a wide variety of different hospitals (61 institutions) across the UK, wards and patients 20 
characteristics.  21 
 Data were collected at the patient-level providing information on the paediatric antimicrobial 22 
prescribing in secondary care adjusted on the case-mix.  23 
 Only volunteer hospitals were including in this cross sectional study leading to potential selection 24 
biases and limited temporal relationship between antimicrobial prescribing and covariates. 25 
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 No consensus exists for measuring antibiotic prescribing in children as DDD/100 inpatients is not a 1 
validated measure for this population.  2 
  3 
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INTRODUCTION  1 
The increasing levels of antimicrobial resistance (AMR) are strongly correlated with 2 
inappropriate use of antibiotics. 
1 2
 Recent United Kingdom (UK) and international reports have 3 
advocated the critical need to monitor and control the use of existing antibiotics since the number of 4 
new classes of antibiotics has dramatically decreased over last 40 years. 
3-5
 Antimicrobial 5 
Stewardship Programmes (ASP), defined as comprehensive quality improvement activities for 6 
optimising antimicrobial prescribing and minimising resistance, have been widely adopted in adult 7 
care settings, 
6 7
 but still remain limited in children’s units. 
8 9
 The heterogeneity in age and weight of 8 
children, as well as the lack of standardised method to quantify antibiotic use in paediatrics, 9 
increases the challenge of determining and benchmarking the appropriateness of prescribing within 10 
or between children institutions; 
10-12
 and children are often excluded from comparative studies on 11 
antibiotic use. 
13 14
 12 
The National Health Service England, Commissioning for Quality and Innovation for 13 
antimicrobial resistance (AMR CQUIN) 2016/17, aims to reduce by 1% or more per year the total 14 
antibiotic consumption and the use of certain broad-spectrum antibiotics considered as critical 15 
antibiotics, (carbapenems and piperacillin-tazobactam), in secondary care. 
15-17
 However, robust 16 
baseline antibiotic use data, so far developed for adults, are lacking for hospitalised children while 17 
they are key to measure the impact of the proposed strategies and to identify room for 18 
improvement. Two international study have proposed to describe and compare the use of 19 
antimicrobials in children across Europe and worldwide using various quality indicators, 
18 19
 but no 20 
comparable detailed information on antibiotic use in hospitalised children in UK is available.  21 
The aim of our study is to describe, compare and explain the prescription pattern of 22 
antibiotics across paediatric units in the UK collected in a cross-sectional point prevalence survey 23 
(PPS) carried out as part of the Antibiotic Resistance and Prescribing in European Children (ARPEC) 24 
project. 
20 21
 We also proposed to use the simple PPS to apply AMR CQUIN quality indicators  to 25 
Page 6 of 27
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
6 
 
provide a baseline of antibiotic prescribing in children to measure the impact of the current and 1 
future national strategies.  2 
 3 
METHODS 4 
Study design and settings 5 
Detailed antimicrobial prescribing data were collected for all inpatients under 18 years-old 6 
present in a participating hospital’s paediatric and neonatal wards at 8am since at least midnight. 7 
Data collection included a wide variety of different hospitals, wards and patient characteristics to be 8 
as representative as possible of hospitalised children in the UK. Data were collected on paper forms, 9 
anonymously entered, validated and reported online through the ARPEC-PPS program. Information 10 
on surgical prophylaxis was captured for the previous 24 hours. Antimicrobial agents were analysed 11 
in accordance with the Anatomical Therapeutic Chemical (ATC) Classification (World Health 12 
Organisation Collaborative Centre for Drug Statistics Methodology, 2013). 
22
 To facilitate the data 13 
collection on underlying diagnosis (defined as a pre-existing comorbidity in addition to the diagnosis 14 
of infection for which patients are prescribed antibiotics) and reason for treatment with antibiotics, 15 
predefined lists of grouped items were used.
23
 The full method is described elsewhere by Versporten 16 
et al. 
21
  17 
 18 
Data extraction 19 
For this study, we extracted and analysed data from 61 paediatric units in the UK which 20 
participated in the ARPEC-PPS organised in March-April 2011 (feasibility survey), September-21 
November 2011 (worldwide pilot ARPEC-PPS) 
21
 and October-December 2012 (full worldwide ARPEC-22 
PPS). 
19
 All inpatients under 18 years of age admitted to a paediatric ward were included. We 23 
excluded infants on neonatal units and those on children’s wards aged under 28 days of age. We 24 
analysed antibacterials for systemic use (ATC J01). 25 
 26 
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Data analysis 1 
Descriptive analysis 2 
Demographic data, presence or not of an underlying chronic condition, current diagnosis, 3 
hospital-acquired infections versus community-acquired infections, therapeutic versus prophylactic 4 
prescribing, and antibiotic type, dosing and route of administration were analysed and compared 5 
between 44 District General Hospitals, which provide secondary care, and 17 Tertiary Referral 6 
Hospitals, which provide tertiary or specialised care. 7 
 8 
Metrics for measuring antibiotic use 9 
  We compared two different metrics of antibiotic prescribing within and between hospitals: 10 
(i) The proportion of children on antibiotics (prevalence rate) with 95% confidence intervals (CIs); (ii) 11 
The Defined Daily Doses per 100 inpatients (DDD/100 inpatients), as recommended in the AMR 12 
CQUIN. 
17 24
 Antibiotic consumption in grams was converted into DDD using the 2013 release of the 13 
ATC Classification. 
22
 The denominator “inpatients” was defined in this study as the sum of inpatients 14 
in the hospital at 8:00am.  15 
 16 
Quality indicators for national benchmarking between UK hospitals  17 
We explored the different inpatient antibiotic prescribing quality indicators proposed by CQUIN 18 
NHS England for antimicrobial resistance. 
17
 19 
1. The total amount of antibiotics prescribed using both metrics, the proportion of children 20 
receiving antibiotics and DDD/100 inpatients in different age bands. A funnel plot was used 21 
to graphically compare antibiotic prescribing between hospitals, to adjust for different 22 
hospital sizes and to identify outliers.
25
 This takes account of the variable number of cases by 23 
institution by plotting the proportion of children on antibiotics against the sample size for 24 
each hospital using a binomial distribution and 95% CI (~2 standard deviation). We also 25 
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displayed antibiotic prescribing in DDD/100 inpatients for each hospital, as well as the 1 
median and interquartile range for each age band.  2 
2. The use of the carbapenems and the use of piperacillin-tazobactam, which are both 3 
considered critically important antibiotics against extended-spectrum beta-lactamase 4 
producing Gram negative bacteria. 
3
 The proportions of children on carbapenems and 5 
piperacillin-tazobactam, as well as the amount of these drugs prescribed in DDD/100 6 
inpatients, were monitored and compared between institutions after adjusting for hospital 7 
type (district general hospitals versus tertiary referral hospitals) and presence of underlying 8 
disease.  9 
 10 
Statistical analyses 11 
We conducted comparative analyses to determine the balance between district general 12 
hospitals and tertiary referral hospitals using tests of proportions (e.g., Chi-square analysis, Fishers 13 
exact test), and tests of central tendency (e.g., ANOVA, sign rank). Mean total daily doses were 14 
compared by unpaired two-sample t-test. All p-values were based on two-tailed test with p-15 
value<0.05 for significance. Statistical analysis was performed using STATA version 12 (STATA Corp, 16 
College Station, Texas). 17 
 18 
Ethics 19 
The responsible UK Research Ethics Committee was approached to establish the need for a 20 
formal evaluation. Written confirmation was provided that within the UK framework a fully 21 
anonymised point prevalence survey constituted surveillance and that formal review by the 22 
Research Ethics Committee was not required. 23 
 24 
RESULTS 25 
 26 
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Patient demographics 1 
A total of 1247 (40.9%) of 3047 surveyed UK paediatric inpatients were receiving 2 
antimicrobials. Overall 1348 indications were recorded for 1247 inpatients with a total of 1858 3 
antibiotic prescriptions. The median age of exposed children was 2 years (IQR=0.083-8). More than 4 
two-thirds of inpatients were recruited from tertiary care centres, and from General Paediatric and 5 
Paediatric Surgery wards (Supplemental Table).  6 
Age differences by speciality were seen among children on antibiotics. For general paediatrics, the 7 
median age of exposed children was 2 years (IQR=0.75-6), for surgery 5 years (IQR=1.25-11), for 8 
paediatric intensive care units (PICU) 0.71 years (IQR=0.08-3), for haematology-oncology-transplant 9 
6 years (IQR=2-11) and for other medical specialties 3 years (IQR=0.75-9). 10 
 11 
Total use of antibiotics 12 
Proportion of children on antibiotics 13 
Table 1 shows that the proportion of children on antibiotics and the number of prescribed 14 
antibiotics was significantly higher in tertiary hospitals (43.0%, CI95% 40.9-45.1, 40 different 15 
prescribed antibiotics) than in district general hospitals (36.4%, CI95% 33.4-39.4, 30 different 16 
prescribed antibiotics, p-value=0.001). About two-thirds of inpatients in intensive or specialist care 17 
wards (PICU and haematology-oncology-transplant) were prescribed antibiotics in high specialist 18 
care areas compared to about one third in general paediatrics and surgery. Multiple antibiotics were 19 
also used more frequently in children admitted to PICU (77/145, 53.1%, CI95% 45.0-61.2) and 20 
haematology-oncology-transplant units (63/92; 68.5%, CI95% 59.0-78.0) compared to children in 21 
paediatric surgery (93/214; 43.5%, CI95% 36.8-50.1) and general paediatrics (199/554, 35.9%, CI 95% 22 
31.9-39.9).  23 
Among all children receiving antibiotics, 60.9% (CI95% 57.5-64.4) of children had an 24 
underlying disease compared with 39.1% (CI95% 34.7-43.4) of previously healthy children. Exposed 25 
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children were more likely to be younger (69.5% exposed below 7 years of age compared to 30.5% at 1 
7 years and older).  2 
Of 1348 indications, a diagnosis of lower respiratory, urinary tract, skin and soft tissue, bone 3 
or joint infection, pyrexia and gastrointestinal infection was recorded in 42.2% (CI 38.1-46.3) 4 
compared to 18.2% (CI 13.4-23.0) with a diagnosis of severe infections, i.e. sepsis, catheter-related 5 
bloodstream infection, central nervous system infection or febrile neutropenia. For exposed 6 
children, treatment for community-acquired infections (CAI) was almost 4 times more common 7 
(59.1%, CI 55.7-62.5) than for healthcare-associated infection (15.7%, CI 10.8-20.6). Finally, about a 8 
quarter of children on antibiotic therapy received either medical (17.3%) or  surgical (6.8%) 9 
prophylaxis. 10 
Proportion of prescriptions for parenteral administration versus oral 11 
Parenteral was the main prescribed route for administrating antibiotics, with more than 60% 12 
of the prescriptions in district general hospitals and tertiary referral hospitals. Parenteral antibiotics 13 
were highly prescribed in PICU (81.6% of the prescriptions), for previous healthy children (70.1% of 14 
the prescriptions), for surgical infections (89.8% of the prescriptions) and for sepsis, central nervous 15 
system infections and febrile neutropenia (96.4% of the prescriptions). 16 
 17 
Figure 1 shows the funnel plot of the proportion of children on antibiotic for each 18 
institution. Hospitals with a proportion outside the funnel plot’s 2 standard deviation control limits 19 
are considered to be potential outliers. 7/61 institutions were identified as potential “high 20 
prescribers”, 2 district general hospitals (21 children on antibiotics) and 5 tertiary referral hospitals 21 
(322 children on antibiotics). For the 2 district general hospitals, all children on antibiotics were from 22 
general paediatric wards, aged under 7 years old for 76.2% of them (mainly aged between 1-6), with 23 
52.4% of them having an underlying disease and 80.1% with a common bacterial infection (LRTI, UTI, 24 
SSTI, joint bone tissue infection). For the 5 tertiary hospitals, a high proportion of children on 25 
antibiotics (30.1%) were from haematology/oncology/transplant units and PICU, with a total of 26 
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71.4% of children having an underlying disease and 22.7% of them presenting with a severe infection 1 
(Sepsis/CRBSI/CNS/febrile neutropenia) while 21.1% were on medical prophylaxis. 73.9% of the 2 
children were aged below 7 years old (35.4% <1 and 38.5% between 1-6). 3 
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Table 1: Proportion of children prescribed antibiotics in paediatric acute care settings across the United Kingdom (years 2011, 2012) 
 N patients treated 
with antibiotic 
Proportion of children 
on antibiotic % (CI95) 
N antibiotic prescriptions 
(Total of different prescribed antibiotics) 
Parenteral administration 
n (% of prescriptions ) 
District general hospitals (n=958 Patients) 349 36.4 (33.4-39.4) 479 (30) 291 (60.8) 
Tertiary referral hospitals (n=2089 Patients) 898 43.0 (40.9-45.1) 1379 (40) 861 (62.4) 
General Paediatric n=1477 554 37.5 (35.0-40.0) 791 (37) 467 (59.0) 
PICU- n=226 145 64.2 (57.9-70.5) 228 (27) 186 (81.6) 
Paediatric Surgery n=597 214 35.8 (32.0-39.6) 321 (29) 223 (69.5) 
Haematology-Oncology-Transplant n=144 92 63.9 (56.1-71.7) 156 (24) 77 (49.4) 
Others n=603 242 40.1 (36.2-44.0) 362 (31) 199 (55.0) 
Total (n patients = 3047) 1247 40.9 (39.2-42.6) 1858 (41)  
 N patients treated 
with antibiotic 
(N=1247) 
Proportion among 
total children on 
antibiotics % (CI95)  
N antibiotic prescriptions 
(Total of different prescribed antibiotics) 
Parenteral administration 
n (% of prescriptions ) 
No underlying disease 487 39.1 (34.7-43.4) 689 (30) 483 (70.1) 
Underlying disease 760 60.9 (57.5-64.4) 1169 (41) 669 (57.2) 
Aged <1 year 347 27.8 (23.1-32.6) 500 (29) 337 (67.4) 
Aged 1-6 years 520 41.7 (37.5-46.0) 734 (31) 413 (56.3) 
Aged 7-11 years 174 14.0 (8.8-19.1) 259 (32) 159 (61.4) 
Aged > 12 years 206 16.5 (11.4-21.5) 363 (36) 243 (66.9) 
 N indications for 
antibiotics 
(N=1348) 
Proportion % (CI95) N antibiotic prescriptions 
(Total of different prescribed antibiotics) 
Parenteral administration 
n (% of prescriptions ) 
Surgical infection 74 5.5 (0.3-10.7) 137 (15) 123 (89.8) 
Surgical prophylaxis 92 6.8 (1.7-11.9) 123 (17) 95 (77.2) 
Medical prophylaxis 233 17.3 (12.4-22.16) 285 (29) 25 (8.8) 
Sepsis/CRBSI/CNS/febrile neutropenia* 246 18.2 (13.4-23.0) 385 (22) 371 (96.4) 
URTI* 73 5.4 (0.2-10.6) 90 (14) 42 (46.7) 
LRTI/UTI/SSTI/Joint-Bone/Pyrexia/GITI* 569 42.2 (38.1-46.3) 764 (35) 458 (60.0) 
Other/unknown 61 4.6 (0.0-9.7) 74 (22) 38 (51.4) 
Community-Acquired Infection 797 59.1 (55.7-62.5)  1121 (34) 774 (69.1) 
Hospital-Acquired Infection 211 15.7  (10.8-20.6) 298 (28) 240 (80.5) 
Other (prophylaxis or unknown) 340 25.2 (20.6-29.8) 439 (34) 138 (31.4) 
Total  1348  1858 (41)  
*CRBSI=Catheter-Related bloodstream Infection; CNS= Central Nervous System; URTI=Upper Respiratory Tract Infection; LRTI= Lower Respiratory Tract Infection; UTI=Urinary 
Tract Infection; SSTI=Skin and Soft Tissue Infection; GITI=Gastro Intestinal Tract Infection
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Total usage of antibiotics in children in DDD/100 inpatients 1 
Table 2 illustrates the total usage of antibiotics in DDD/100 inpatients for each age category 2 
per type of hospital and specialty. The total amount of antibiotics used is slightly higher in tertiary 3 
hospitals than in district general hospitals (37.8 versus 30.7 DDD/100 inpatients), except for children 4 
aged 1-6 years-old. The use of antibiotics is about twice as common in haematology-oncology-5 
transplant units compared to other specialties, especially for patients above 12 years-old. For 6 
patients below 1 year-old, the use of antibiotics is substantially higher in PICU compared to other 7 
specialties.  8 
 9 
Table 2: Total usage of antibiotics in DDD/ 100 inpatients in paediatric acute care settings 10 
across the United Kingdom, year 2011-2012 11 
 DDD/100 inpatients 
 Aged <1yr Aged 1-6yrs Aged 7-11yrs Aged >12yrs 
District general hospitals n=958 3.2 12.3 6.0 9.2 
Tertiary referral hospitals n=2089 4.0 10.5 7.1 16.2 
General Paediatric n=1477 3.9 11.9 4.7 12.8 
PICU- n=226 7.5 12.7 6.4 10.9 
Paediatric Surgery n=597 2.1 9.0 10.7 15.7 
Haematology-oncology-transplant n=144 0.45 14.2 14.0 31.7 
Others n=603 4.3 9.7 6.3 11.9 
Total 32.9 64.8 118.3 207.5 
 12 
The total prescribed antibiotics in DDD/100 inpatients per age band is shown Figure 2. A wide range 13 
of antibiotic use is observed among the 61 centres for patients aged between 12-18 years-old, 14 
whereas the three other groups show greater homogeneity between institutions in antibiotic usage. 15 
The total prescribed antibiotics is harmonised between district general hospitals and tertiary referral 16 
hospitals across the four age groups.  17 
 18 
Carbapenems and piperacillin-tazobactam  19 
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Table 3 shows that among children receiving at least one antibiotic, the proportion of 1 
children on carbapenems was significantly higher in tertiary hospitals than in district general 2 
hospitals (respectively, n=54, 6.0% versus n=7, 2.0%, p-value=0.003). The same results were 3 
observed for the total amount of DDD/100 inpatients. Less than half of the children on carbapenems 4 
had at least one underlying disease recorded for district general hospitals, while more than 9 out of 5 
10 had an underlying disease for tertiary hospitals. In district general hospitals, the general 6 
paediatric wards were the main prescribers of carbapenems as an empirical treatment, whereas in 7 
tertiary hospitals, about 43% of the prescriptions were targeted and PICU were the main prescribers.   8 
The amount of piperacillin-tazobactam in DDD/100 inpatients was also surprisingly 2-fold higher in 9 
district general hospitals than in tertiary hospitals. However, the proportion of children on 10 
piperacillin-tazobactam among all the children on antibiotics was much higher in tertiary hospitals. 11 
In district general hospitals, most of the patients were prescribed piperacillin-tazobactam in 12 
paediatric general wards, as an empirical treatment when they had at least one underlying disease, 13 
whereas, in tertiary hospitals, piperacillin-tazobactam was prescribed in haematology-oncology-14 
transplant wards in presence of an underlying disease.  15 
 16 
 17 
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Table 3: Total usage of carbapenems and piperacillin-tazobactam in paediatric acute care settings across the United Kingdom, year 2011-
2012 
*% among the total number of children on antibiotics per type of hospitals 
*% among the total number of children on antibiotics per type of hospitals 
**% among the number of children on carbapenems or piperacillin-tazobactam 
 
  
 Carbapenems Piperacillin-tazobactam 
 District general hospitals 
(349 children on antibiotics) 
Tertiary referral hospitals 
(898 children on antibiotics) 
District general hospitals 
(349 children on antibiotics) 
Tertiary referral hospitals 
(898 children on antibiotics) 
Total DDD/100 inpatients 36.4 56.0 39.7 20.0 
Total children n (%)* 7 (2.0) 54 (6.0) 14 (4) 68 (7.6) 
General Paediatric n children (%)** 6 (85.7) 14 (25.9) 11 (78.6) 9 (13.2) 
PICU n children (%) 1 (14.3) 17 (31.5) 0 12 (17.6) 
Paediatric Surgery n children (%)  0 6 (11.1) 3 (21.4) 7 (10.3) 
Haematology-oncology-transplant n 
children (%) 
0 10 (18.5) 0 19 (27.9) 
Others n children (%) 0 7 (13.0) 0 21 (30.9) 
Underlying disease versus previously 
healthy children n children (%)** 
3 (42.9) 49 (90.7) 12 (85.7) 67 (98.5) 
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DISCUSSION 1 
We describe a unique inpatient antibiotic prescribing dataset from 61 paediatric units across 2 
the UK. Our results identified areas of potential improvement for appropriate prescribing at the 3 
patient-level adjusting for risk factors (age, underlying diseases, infections, specialties), using the 4 
paediatric point prevalence method developed by the ARPEC project. Our results provide the 5 
baseline for future benchmarking to monitor national strategies for optimal antimicrobial 6 
prescribing in children, particularly the CQUIN NHS England scheme 2015/16 for AMR.  7 
A total of 1247 out of 3047 surveyed admitted children were on antibiotics in this study. The 8 
proportion of children receiving antibiotics showed a wide variation between district general 9 
hospitals and tertiary referral hospitals, but also a wide variation within both groups of hospitals. 10 
The presence of case-mix and specialities, such as haematology-oncology-transplant and PICU, may 11 
be responsible for some of the differences observed in prescribing. Figure 1 highlighted that a total 12 
of 7/61 (11.5%) institutions, mainly the haematology-oncology-transplant and PICU units of the 13 
tertiary hospitals, were identified as potential “high prescribers”. However, potential “high 14 
prescribers” in general district hospitals were only general paediatric units with less than half of the 15 
patients having an underlying disease. 16 
We also highlighted a proportion of patients on medical prophylaxis (17.3%) similar to other 17 
countries (16.9% in Italy and 14.8% on average worldwide). 
19 26
 Medical prophylaxis appeared to be 18 
one of the most common indications for antibiotic prescribing in children (The reason, duration and 19 
need for prophylaxis should be further assessed for quality improvement through antimicrobial 20 
stewardship programmes across paediatric units in the UK, as it is in adult settings.
27
  21 
The total usage of antibiotics in DDD/100 inpatients per age group showed a higher 22 
consumption in haematology-oncology-transplant units compared to the other specialties, except 23 
for under 1 year-old receiving antibiotics on PICU. Children admitted to haematology-oncology-24 
transplant units or to PICU were more likely to receive a combination of antibiotics than general and 25 
surgical paediatric patients, which may directly impact exposure measured in DDD/1000 inpatients.   26 
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Carbapenems and piperacillin-tazobactam, were mainly prescribed empirically, and to 1 
children with underlying conditions in tertiary hospitals. These results are expected and will serve as 2 
a benchmark in future evaluations. However, we did not predict that general paediatric units were 3 
high prescribers for these two drugs in both district general and tertiary hospitals. With the spread 4 
of extended-spectrum-beta-lactamase producing Enterobacteriaceae in adults 
28
 but also in 5 
paediatrics over the last decade, 
29
 and the increase of small outbreaks of multidrug resistant 6 
organisms in UK paediatric hospitals, 
30
 the prescribing pattern for these critical drugs may change in 7 
the future and needs to be better monitored, especially in the general paediatric units for previously 8 
healthy children.  9 
There remains a lack of consensus regarding the optimal metric to assess paediatric antimicrobial 10 
use, which is an important limitation. The use of DDD/100 inpatients (DDD being defined as the 11 
amount of antibiotic prescribed for a 70kg average adult weight for its main indication) proposed by 12 
CQUIN AMR is not a perfect measure, especially in children with a wide range of weights (from 5kg 13 
in a 3 months-old to over 100kg in obese adolescents). As DDD is weight and dose-dependent, 
31
 we 14 
decided to compare overall drug exposure using DDD/100 inpatients in age bands as proposed by 15 
Porta et al.
24
 Despite DDD/100 inpatients being advocated by the WHO Collaborating Centre for 16 
Drug Statistics and Methodology, “days of therapy” could have advantages over DDD measures, 17 
because the impact of variation in absolute dose is limited for this metric. 
11 31
 However, longitudinal 18 
studies or access to electronic-prescribing systems for each hospital in the UK would be required to 19 
calculate this, which may not be realistic in the near future. 
32
 For now, DDD/100 inpatients could be 20 
used to monitor changes within units over time as long as the case mix remains the same. While we 21 
have strongly promoted this study to include a large number of paediatric centres from a wide 22 
variety of different hospitals, wards and patient characteristics across the UK, only volunteer centres 23 
were recruited, with the potential for selection biases. Finally, the PPS methodology provided 24 
limited evidence on the temporal relationship between the antimicrobial prescribing in children and 25 
the covariates of interest. 26 
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In conclusion, we provide a robust baseline for antibiotic prescribing in hospitalised children 1 
in relation to current national stewardship efforts in the UK. Repeated PPS 
33
 need to be part of the 2 
paediatric antibiotic stewardship strategy in order to identify prescribing trends over time, to 3 
evaluate the efficacy of antimicrobial stewardship programmes and to tackle the issue of suboptimal 4 
antibiotic use, especially on antibiotic dosing.
34
 International standardised PPS with further linkage 5 
between antibiotic prescribing and resistance will be critical to characterise appropriate use of 6 
antibiotics in hospitalised children globally and to propose guidance on the management of 7 
paediatric infections taking into account resistance profiles.  8 
 9 
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Supplemental table: Characteristics of paediatric hospital across the United Kingdom (during the two one-
day point prevalence survey in 2011-12) 
 
 N patients (%) N beds Bed occupancy 
District general hospitals  958 (31.4) 1604 59.7% 
Tertiary referral hospitals 2089 (68.6) 2542 82.2% 
General Paediatric  1477 (48.5) 2235 66.1% 
PICU - Paediatric 
Intensive Care Unit 
226 (7.4) 265 85.3% 
Paediatric Surgery 597 (19.6) 789 75.7% 
Haematology-oncology-
transplant 
144 (4.7) 195 73.8% 
Others 603 (19.8) 662 91.1% 
Total (N centres = 61) 3047 4146 73.5% 
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STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies  
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
Done  page 1 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found    Done page 3 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
Done page 4 
Objectives 3 State specific objectives, including any prespecified hypotheses   Done pages 4-5 
Methods 
Study design 4 Present key elements of study design early in the paper  Done page 5 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection  Done page 5 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants   Done page 5 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable  Done page 6 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group   Done page 6 
Bias 9 Describe any efforts to address potential sources of bias  Done page 6-7 
Study size 10 Explain how the study size was arrived at  Done pages 5 and 7 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why  Done pages 6-7 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding  
Done page 7 
(b) Describe any methods used to examine subgroups and interactions  Done pages 
6-7 
(c) Explain how missing data were addressed  No missing data 
(d) If applicable, describe analytical methods taking account of sampling strategy 
NA 
(e) Describe any sensitivity analyses NA 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed  Done page 7 
(b) Give reasons for non-participation at each stage  All participants eligible 
participated at the Point Prevalence Survey 
(c) Consider use of a flow diagram   Not necessary here because all the patients 
eligible were included in the analyses 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders Done page 7 
(b) Indicate number of participants with missing data for each variable of interest 
Done Table 1 and page 7 
Outcome data 15* Report numbers of outcome events or summary measures Done table 1-2 and 3 
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pages 8-12 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included Done table 1-2-3 
(b) Report category boundaries when continuous variables were categorized Done 
table 1-2 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period Not relevant 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses  NA 
Discussion 
Key results 18 Summarise key results with reference to study objectives Done p14-15 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias Done p15 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Done page 15-16 
Generalisability 21 Discuss the generalisability (external validity) of the study results Done pages 15-16 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based Done page 17 
 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org. 
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